Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
criteria
gamma knife
pseudoprogression
radionecrosis
stereotactic radiotherapy
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
26
03
2020
revised:
23
04
2020
accepted:
24
04
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
20
7
2021
Statut:
ppublish
Résumé
The optimal sequence of stereotactic radiotherapy (SRT) and immune checkpoint inhibition (ICI) and assessment of response in patients with brain metastases from melanoma remain challenging. We reviewed clinical and neuroimaging data of 62 patients with melanoma, including 26 patients with BRAF-mutant tumours, with newly diagnosed brain metastases treated with ICI alone (n=10, group 1), SRT alone or in combination with other systemic therapies (n=20, group 2) or ICI plus SRT (n=32, group 3). Response was assessed retrospectively using response evaluation criteria in solid tumours (RECIST) V.1.1, response assessment in neuro-oncology (RANO) and immunotherapy RANO (iRANO) criteria. MRI follow-up from 43 patients was available for central review. Patients treated with ICI alone showed no objective responses and had worse outcome than patients treated with SRT without or with ICI. RECIST, RANO and iRANO criteria were concordant for complete response (CR) and partial response (PR). RANO called progression earlier than RECIST for clinical deterioration without MRI progression in some patients. Progression was called later when using iRANO criteria because of the need for a confirmatory scan. Pseudoprogression was documented in seven patients: three patients in group 2 and four patients in group 3. Radionecrosis was documented in seven patients: two patients in group 2 and five patients in group 3. Regression of non-irradiated lesions was seen neither in two patients treated with SRT alone nor in five patients treated with SRT plus ICI, providing no evidence for rare abscopal effects. Pseudoprogression is uncommon with ICI alone, suggesting that growing lesions in such patients should trigger an intervention. Pseudoprogression rates were similar after SRT alone or SRT in combination with ICI. Abscopal effects are rare or do not exist. Response assessment criteria should be considered carefully when designing clinical studies for patients with brain metastases who receive SRT.
Sections du résumé
BACKGROUND
The optimal sequence of stereotactic radiotherapy (SRT) and immune checkpoint inhibition (ICI) and assessment of response in patients with brain metastases from melanoma remain challenging.
METHODS
We reviewed clinical and neuroimaging data of 62 patients with melanoma, including 26 patients with BRAF-mutant tumours, with newly diagnosed brain metastases treated with ICI alone (n=10, group 1), SRT alone or in combination with other systemic therapies (n=20, group 2) or ICI plus SRT (n=32, group 3). Response was assessed retrospectively using response evaluation criteria in solid tumours (RECIST) V.1.1, response assessment in neuro-oncology (RANO) and immunotherapy RANO (iRANO) criteria. MRI follow-up from 43 patients was available for central review.
RESULTS
Patients treated with ICI alone showed no objective responses and had worse outcome than patients treated with SRT without or with ICI. RECIST, RANO and iRANO criteria were concordant for complete response (CR) and partial response (PR). RANO called progression earlier than RECIST for clinical deterioration without MRI progression in some patients. Progression was called later when using iRANO criteria because of the need for a confirmatory scan. Pseudoprogression was documented in seven patients: three patients in group 2 and four patients in group 3. Radionecrosis was documented in seven patients: two patients in group 2 and five patients in group 3. Regression of non-irradiated lesions was seen neither in two patients treated with SRT alone nor in five patients treated with SRT plus ICI, providing no evidence for rare abscopal effects.
CONCLUSIONS
Pseudoprogression is uncommon with ICI alone, suggesting that growing lesions in such patients should trigger an intervention. Pseudoprogression rates were similar after SRT alone or SRT in combination with ICI. Abscopal effects are rare or do not exist. Response assessment criteria should be considered carefully when designing clinical studies for patients with brain metastases who receive SRT.
Identifiants
pubmed: 32747372
pii: S2059-7029(20)32647-8
doi: 10.1136/esmoopen-2020-000763
pmc: PMC7401999
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2019 Mar;110:11-20
pubmed: 30739835
Lancet Oncol. 2018 Aug;19(8):e366
pubmed: 30102216
Radiother Oncol. 2017 Oct;125(1):80-88
pubmed: 28916225
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Neurooncol. 2020 Jan;146(1):181-193
pubmed: 31836957
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
J Neurosurg. 2011 Mar;114(3):769-79
pubmed: 20524829
Cancer. 2019 Dec 1;125(23):4193-4202
pubmed: 31398264
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
Eur J Cancer. 2019 May;112:38-46
pubmed: 30909072
J Immunother Cancer. 2019 Apr 11;7(1):102
pubmed: 30975225
Ann Oncol. 2017 Mar 1;28(3):634-641
pubmed: 27993793
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816
pubmed: 29063850
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
J Neurooncol. 2014 May;118(1):109-16
pubmed: 24532241
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Melanoma Res. 2019 Apr;29(2):187-195
pubmed: 30802230